Novartis's $30 billion wipeout hands pharma's activist playbook a new trigger: trial failure

Within five trading days, Novartis went from reaffirming full-year guidance to facing an open demand for a board overhaul. On Sept 4 the Lp(a)HORIZON trial of pelacarsen — licensed from Ionis Pharmaceuticals in 2019 for cardiovascular disease — failed to show a reduction in heart attacks, strokes, or cardiovascular death despite cutting Lp(a) levels by up to 80%. Shares slipped about 3%. Four days later the HARBOR Phase III of del-desiran in myotonic dystrophy type 1 (DM1) — the centerpiece asset Novartis acquired in its $12 billion Avidity Biosciences takeover that closed on Feb 27, 2026 — missed its primary endpoint of video hand opening time, and the stock collapsed roughly 11%, its worst single-day drop on record.

The two readouts are not symmetric. Pelacarsen was licensed in, so the failure is primarily an option-value loss — analyst peak sales estimates had run $4–5 billion, and Ionis sold most of the royalty stream to Royalty Pharma in 2023 for $500 million upfront. Del-desiran is a balance-sheet hit: with roughly $11.3 billion of the $12 billion Avidity price allocated to identifiable intangible assets, a failed Phase III in the lead program raises a concrete writedown question for Novartis's Q3 results.

The reason Samra is pushing the M&A and compensation angles — not operations — is that Novartis is still delivering on the commercial side. Q2 2026 net sales of $14.4 billion grew 1% cc (3% USD), core operating income held flat at $5.9 billion, and full-year guidance was reaffirmed on July 21, 2026. Net income of $3.3 billion did fall 19% cc, but that reflected higher amortization and tax, not a demand problem. The Avidity deal was a science bet, not a revenue bet; Samra's argument is that the science bet was overpriced and the board never built a capital-allocation check to prove otherwise.

The 2025–2026 pattern across pharma activism is that nearly every campaign — Pfizer/Starboard, Astellas/Farallon, Novo Nordisk/Parvus, Medtronic/Elliott — has had an M&A or pipeline-productivity thesis, per A&O Shearman. What makes the Novartis case different is the trigger: trial failure on a $12 billion deal asset, not financial underperformance on a legacy business. Samra is essentially arguing that the board's strategic judgment — not its cost discipline — failed, and that compensation metrics designed to exclude the resulting writedowns will hide that fact from shareholders.

In the days and quarters ahead, the catalysts stack up: any Avidity-related intangible impairment in Q3 results would put a hard number on Samra's writedown criticism, while del-zota's FDA decision (priority review accepted Sept 2026) and del-brax's next FDA interaction in FSHD will determine how much of the $11.3 billion intangible base survives. Compensation-committee changes and any public response to Samra from Chair Giovanni Caforio (re-elected at the March 6, 2026 AGM) will move first; a director nomination or public proxy fight would be a 2027 event, timed to the next AGM cycle.

The reason this matters beyond Novartis is the read-across. With ~$47 billion of global pharma revenue at risk on average over the next four years from patent cliffs (per IQVIA Institute data cited by A&O Shearman), big-pharma boards are about to pay top dollar for late-stage assets to refill their pipelines. Artisan's public test of Novartis's board is now the template shareholders at Pfizer, AstraZeneca, Roche, and Sanofi will reach for the moment a $5 billion-plus deal's lead asset misses a Phase III endpoint — the demand will no longer be \"explain the strategy,\" it will be \"name the directors responsible for the deal.\"